SCHEMBL17098764

SCHEMBL17098764

CC(CN(Cc1ccc(F)cc1)C(=O)c1cnn([C@H]2CC[C@H](C(=O)O)CC2)c1C(F)(F)F)c1c(Cl)cccc1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 6/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPT P10636 1/20 0.34
S1PR1 P21453 1/20 0.34
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
NR3C1 P04150 5/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
JAK1 P23458 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17098766 1.00 TAS2R14 (0.35) TAS2R14ALDH1A1MAPTS1PR1EGFR
SCHEMBL17098573 0.93 BACE1 (0.35) TAS2R14ALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL17098575 0.93 BACE1 (0.35) TAS2R14ALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL17098675 0.92 TAS2R14 (0.34) TAS2R14ALDH1A1MAPTEGFRERBB2
SCHEMBL17098672 0.92 TAS2R14 (0.34) TAS2R14ALDH1A1MAPTEGFRERBB2
SCHEMBL17097992 0.86 TAS2R14 (0.34) TAS2R14ALDH1A1MAPTS1PR1EGFR
SCHEMBL17097996 0.86 TAS2R14 (0.34) TAS2R14ALDH1A1MAPTS1PR1EGFR
SCHEMBL17097903 0.85 TAS2R14 (0.37) TAS2R14ALDH1A1MAPTEGFRERBB2
SCHEMBL17097899 0.85 TAS2R14 (0.37) TAS2R14ALDH1A1MAPTEGFRERBB2
SCHEMBL17110623 0.85 TAS2R14 (0.35) TAS2R14ALDH1A1MAPTEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US claimed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US claimed
EP-3110810-B1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LTD (JP) 2018-05-02 EP disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266824-A1 Pyrazole Amide Derivative RORC, RORB, RORA TAS2R14 2628/4885ALDH1A1 923/4885MAPT 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.